March/April 2012, Vol 5, No 2

Business

Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers
Rhonda Greenapple, MSPH
Stakeholder Perspective by Albert Tzeel, MD, MHSA, FACPE
Impact of the Removal of the Monthly Liver Function Test Requirement for Ambrisentan
Louise A. Durst, RN
; John Carlsen, MHA
; Megan Kuchinski, MPH
; Lauren Harner, JD
; Daniel Neves, BA
; Stephanie J. Harris, RN, BSN
; Glenna L. Traiger, RN, MSN, CNS-BC
Stakeholder Perspective by James T. Kenney, Jr, RPh, MBA

Clinical

Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty
Richard J. Friedman, MD, FRCSC
Stakeholder Perspective by Atheer A. Kaddis, PharmD

Editorial

A New Beginning
David B. Nash, MD, MBA